Consistent with these in vitro results, immunohistochemistry using human endometrioid carcinoma clinical specimens demonstrated that cancer cells at the tumor invasive front showed lower ASS1 and DEPTOR expression, and higher ribosomal protein S6 phosphorylation (pS6) than those in the center of the tumor. The gene discussed is ASS1; the disease is endometrioid adenocarcinoma.